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Abstract: Extra virgin olive oil (EVOO) is suggested to be cardioprotective, partly due to its high
phenolic content. We investigated the effect of extra virgin high polyphenol olive oil (HPOO) versus
low polyphenol olive oil (LPOO) on blood pressure (BP) and arterial stiffness in healthy Australian
adults. In a double-blind, randomized, controlled cross-over trial, 50 participants (age 38.5± 13.9 years,
66% female) were randomized to consume 60 mL/day of either HPOO (360 mg/kg polyphenols) or
LPOO (86 mg/kg polyphenols) for three weeks. Following a two-week washout period, participants
crossed over to consume the alternate oil. Anthropometric data, peripheral BP, central BP and arterial
stiffness were measured at baseline and follow up. No significant differences were observed in the
changes from baseline to follow up between the two treatments. However, a significant decrease in
peripheral and central systolic BP (SBP) by 2.5 mmHg (95% CI: −4.7 to −0.3) and 2.7 mmHg (95% CI:
−4.7 to −0.6), respectively, was observed after HPOO consumption. Neither olive oil changed diastolic
BP (DBP) or measures of arterial stiffness. The reductions in SBP after HPOO consumption provide
evidence for a potentially widely accessible dietary intervention to prevent cardiovascular disease in
a multiethnic population. Longer intervention studies and/or higher doses of EVOO polyphenols are
warranted to elucidate the potential effect on DBP and arterial stiffness.
Nutrients 2020, 12, 2272; doi:10.3390/nu12082272 www.mdpi.com/journal/nutrients
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1. Introduction
Cardiovascular disease (CVD) is the leading cause of mortality and morbidity worldwide.
Established risk factors such as hypertension, dyslipidaemia, diabetes and obesity contribute to
9.7 million annual deaths related to CVD globally [1]. The most recent Australian data, collected
between 2017 and 2018, indicates 27% of all deaths (43,477 deaths) were attributed to CVD [2].
A similarly high proportion of Australian adults (~34%) have diagnosed hypertension [3]. Previous
studies have indicated that changes in peripheral and central hemodynamics such as in peripheral
(brachial) and central (aortic) BP and pressure wave reflections contribute to the development of adverse
cardiovascular events [4]. Moreover, stiffening of the central elastic arteries, such as the aorta and the
pulmonary arteries, is an accepted independent predictor of CVD risk and is positively associated with
systolic hypertension [5,6]. Several surrogate markers reflecting vascular health are used in clinical
practice. Pulse wave velocity (PWV), estimated by non-invasive applanation tonometry and pulse wave
analysis, is considered the gold-standard marker of arterial stiffness [7]. Furthermore, systemic arterial
wave reflections, as measured by the augmentation index (AIx), provide additional clinical information
on CVD, while assessment of central BP and pulse pressure (PP) provides further predictive value
beyond the corresponding brachial BP [6,8,9].
Extensive evidence indicates that certain dietary patterns are cardioprotective [10]. The traditional
Mediterranean diet (MedDiet), has been shown to improve CVD risk factors including lipidemic
and glycaemic profile, markers of inflammation and oxidative stress [11,12]. The MedDiet is plant
rich, with staple foods consisting of wholegrain cereals, vegetables, fresh fruit, seafood, legumes,
nuts and red wine [12,13]. Previous studies have demonstrated that MedDiet food components
improve vascular health. Moderate consumption of red wine has been found to reduce BP and
improve arterial stiffness in healthy individuals [14] and patients with coronary artery disease [15,16].
Furthermore, regular consumption of olive oil (OO), which is the principal source of dietary fat in the
MedDiet, has demonstrated BP-lowering effects [17,18].
The reported cardioprotective benefits of OO have been mostly attributed to the presence of variable
concentrations of bioactive compounds, including polyphenols (also referred to as biophenols), mainly
known for their anti-inflammatory and antioxidant properties [12,19,20]. One of the determinants of
final OO polyphenol concentration is the oil extraction procedure [20–22]. In particular, extra virgin
olive oil (EVOO) is obtained by mechanical extraction techniques under conditions that preserve high
polyphenol concentrations, whereas refined OO (ROO) is subject to both physical and/or chemical
processing, which significantly lowers the phenolic content [22]. Although there is some evidence
linking dietary polyphenol intake, including those in virgin OOs, with decreased CVD risk [23,24],
this favourable effect of polyphenols is not currently taken into consideration by dietary guidelines,
thus indicating a need for further relevant evidence.
Our research team recently conducted a meta-analysis of the published literature to determine
the effects of HPOO consumption, compared with LPOO, on cardiovascular markers [19].
This meta-analysis indicated that HPOO can improve outcomes related to cholesterol (total and
high-density lipoprotein (HDL)) and oxidative stress (oxidized low-density lipoprotein (LDL) and
malondialdehyde) compared to the LPOO intervention arm. However, no significant changes were
observed with respect to SBP and DBP after either OO consumption (daily dose ranged between
25 and 75 mL), while none of the included studies reported measures of arterial stiffness. In 2019,
a network meta-analysis reported that EVOO may reduce oxidized LDL (ox-LDL) and LDL cholesterol
compared to ROO and LPOO, respectively, while a dose–response relationship was observed between
higher intakes of OO phenolic compounds and lower SBP and ox-LDL values [25]. As also stated
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in another recent review, most intervention studies investigating the effect of HPOO on CVD risk
markers have been conducted in Mediterranean populations that have high habitual OO intake [26],
thus highlighting the need for additional research on multiethnic populations with different habitual
food cultures. Hence, the aim of the current study was to examine the effect of daily consumption of
(60 mL) raw extra virgin HPOO, compared to LPOO, for 3 weeks, on peripheral and central BP and
arterial stiffness in Australian adults with no previously diagnosed medical condition.
2. Materials and Methods
2.1. Study Population
The OLIVAUS study [20] was conducted according to the Guidelines for Good Clinical Practice
(GCP), the guidelines laid down in the Declaration of Helsinki and the CONSORT reporting
guidelines. All procedures involving human subjects were approved by the Human Research
Ethics Committee of La Trobe University (HEC17-067) and written informed consent was obtained
from all volunteers. The trial protocol has been registered with the Australia New Zealand Clinical
Trials Registry ACTRN12618000706279.
All participants were recruited in Melbourne, Australia, via social media and La Trobe University
email database advertising, word of mouth and posters on campus. A standardized screening
procedure was followed in order to identify eligible participants, who were required to be within the
age range of 18–75 years and a body mass index (BMI) of 18.5–40 kg/m2. Exclusion criteria included
non-English-speaking individuals, pregnant or lactating women, smokers, individuals on a special
type of diet for medical reasons (e.g., gluten free for coeliac disease) and/or with a high habitual OO
intake (>1 tablespoon/day). Exclusion also applied if individuals were taking vitamins or antioxidant
supplements as part of a regular regime and were unable to discontinue their use for the duration of
the trial (with the exception of iron, calcium and Vitamin D). Finally, study subjects taking prescribed
medication (e.g., antihypertensive agents, lipid-lowering drugs, non-steroidal ant-inflammatory drugs)
and those with diagnosed chronic diseases (diabetes, hyperlipidaemia, hypertension, and inflammatory
conditions), gut-related diseases or any other condition that could impair adherence were also excluded.
2.2. Study Design and Procedure
The OLIVAUS study was a double-blind, cross-over, randomized controlled trial (RCT) aiming
to evaluate the effect of extra virgin HPOO consumption on CVD risk markers in comparison with a
commercially available OO which was low in polyphenols (LPOO). Prior to the main study, a pilot
study was conducted with five study participants in order to test the feasibility of the study protocol
and the data collection tools [27]. Enrolled participants were randomly assigned, in a 1:1 ratio, to one of
two treatment arms, i.e., Group (1) extra virgin HPOO/LPOO or Group (2) LPOO/extra virgin HPOO,
using the block-randomization method of a software program for sequence. Blocks of 6 participants
were generated by a senior researcher, who was not directly involved in the participant recruitment
or data collection phase. Allocation of each participant was emailed to the research team at the
commencement of the study by a researcher who was not involved in any participant contact.
Study participants were requested to consume a daily dose of 60 mL of either type of raw OO
over 2 intervention periods of 3 weeks each, in conjunction with their habitual diet. The two types
of OO varied only in their phenolic content (i.e., 360 mg/kg in HPOO vs. 86 mg/kg in LPOO) but
did not differ with respect to the rest of their nutrient composition, including their fatty acid profile.
Two washout periods, of 2 weeks each, during which study participants were instructed to avoid olives
and OO consumption, preceded the first and the second intervention periods of OO administration.
The intervention in the present study was designed with a daily dose of 60 mL OO, which reflects the
habitual intake in populations where the cardioprotective benefits of virgin OO have been previously
reported [19,25,26].
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Participants were provided with OO bottles at the beginning of each intervention period. The OOs
were supplied in dark coloured glass containers to minimise phenolic content loss due to sunlight.
To ensure blinding of the researchers to the OO type, each bottle was assigned a different code number
that was concealed from study participants and research team members. This was disclosed only
after the completion of the statistical analyses. To assess the level of adherence to the intervention,
participants were instructed to return the containers at the end of each intervention period so that
the daily amount of unconsumed OO could be measured and recorded. Study participants were
also instructed to keep a written record of daily OO consumed during each intervention period
using a checklist provided to them. This information was recorded by research team members after
the end of each intervention period. Full details of the study protocol, including a comparison of
the concentrations of total polyphenols and polyphenol subclasses in each of the two types of OOs,
are provided elsewhere [20].
2.3. Measurements
2.3.1. Socio-Demographics, Use of Medication and Dietary Supplements
Socio-demographic data were collected from eligible participants during a scheduled interview at
our trial clinic room located at La Trobe University. Trained researchers conducted all interviews using
a standardized questionnaire. Specifically, the socio-demographic data collected during this interview
included age, gender, language(s) spoken at home, level of education, ethnicity and parental country
of birth. Any medications and dietary supplements taken by the study participants were also recorded.
2.3.2. Dietary Intake
A 3-day food diary was used to collect information on the dietary intake of study participants
during two weekdays and one weekend day (preferably non-consecutive) at baseline and follow up of
each intervention period. Specifically, study participants were instructed to record details on their
intake of food and beverages, including information on the quantity, type/brand and cooking methods
of the consumed items. The level of detail required to be recorded in the diary as well as additional
strategies on how to incorporate raw, uncooked OO in their habitual diet were provided to study
participants at a pre-baseline meeting by a trained nutritionist. The completed food diaries were
returned and checked by the research team members for potential wrong or missing entries during the
scheduled interviews with the study participants. All dietary intake data were analyzed for energy,
macro- and micronutrient content using FoodWorks®9 software (Xyris Software Pty Ltd., Brisbane,
Queensland, Australia).
2.3.3. Physical Activity
Physical activity (PA) was assessed using the Active Australia Survey (AAS) questionnaire [3],
a tool that has been validated in the Australian population. This questionnaire is designed to assess
participation in a range of leisure-time physical activities of light, moderate and vigorous intensity.
The questionnaire consists of eight questions, which assess the number of sessions and total weekly
time (hours and/or minutes) spent for each activity type. Study participants were required to complete
and submit the AAS questionnaire during the week preceding the interviews at the first baseline and
at the last follow-up meeting. The amount of time (in minutes per day) that study participants were
engaged in physical activity of different intensity was calculated and used for data analysis.
2.3.4. Anthropometric Measurements
Anthropometric measurements were conducted four times during the study, i.e., at baseline and
follow up of each intervention period. Body weight and standing height were measured with study
participants in light clothing and barefoot, using a digital scale (WM203, Willawong QLD, Australia),
to the closest 0.1 kg and a wall-mounted stadiometer (SE206, Seven Hills, NSW, Australia) to the
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nearest 0.1 cm, respectively. Waist circumference (WC) was measured to the nearest 0.1 cm, using a
flexible steel tape calibrated in cm with mm graduations (Luftkin W606PM, Sparks, MD, USA) directly
over the skin at the umbilicus level. Body mass index (BMI) was calculated using Quetelet’s equation
(weight (kg)/height (m)2). Using World Health Organization (WHO) cut-off points for BMI, study
participants were classified as underweight (BMI < 18.5 kg/m2), normal weight (BMI 18.5–24.9 kg/m2),
overweight (BMI 25.0–29.9 kg/m2) or obese (BMI ≥ 30 kg/m2) [28]. Furthermore, gender-specific WC
cut-off points proposed by the WHO were also used to categorise study participants for CVD risk:
normal (WC < 94 cm in men and <80 cm in women), high CVD risk (WC 94–102 cm in men and
80–88 cm in women) and very high CVD risk (WC > 102 cm in men and 88 cm in women) [29].
2.3.5. Hemodynamic Indices
Blood Pressure
Peripheral (brachial) and central (aortic) blood pressure (BP) were measured using applanation
tonometry with a SphygmoCor XCEL device (Model XCEL, AtCor Medical, Sydney, Australia),
at baseline and follow-up examinations at each intervention period. Following a minimum of 5 min
rest in the supine position, peripheral brachial systolic BP (SBP) and diastolic BP (DBP) was measured
using a blood pressure cuff affixed to the upper left arm. Three consecutive BP recordings were made
and the average of the last two recordings was used for data analysis. In addition, central SBP and
DBP, as well as PP measures were automatically derived via the brachial BP cuff. The BP categories
recommended by the American College of Cardiology (ACC)/American Heart Association (AHA) were
used to classify study participants into those with Normal BP (SBP/DBP < 120/80 mmHg), Elevated
BP (SBP 120–129 mmHg and DBP < 80 mmHg), Hypertension Stage I (SBP 130–139 mmHg or DBP
80–89 mmHg) and Hypertension Stage II (SBP ≥ 140 mmHg or DBP ≥ 90 mmHg) [9].
Arterial Stiffness
Measures of peripheral and central arterial stiffness, using pulse wave analysis (PWA) and pulse
wave velocity (PWV), were obtained non-invasively with the SphygmoCor XCEL device (Model XCEL,
AtCor Medical, Sydney, Australia). This was carried out using the standard procedure as outlined in
our previous paper [8]. PWA is a non-invasive, valid and reliable technique to investigate mechanical
properties of the arterial tree, using central blood pressures and analysis of systemic arterial wave
reflection. Peripheral arterial stiffness indices of augmentation pressure (AP) and the augmentation
index (AIx) were derived automatically by the device as part of the standard BP measurement procedure.
The AP was calculated as the difference between the first and second systolic peak, while the AIx was
calculated as the percentage contribution that the AP makes to the overall PP (AIx = AP/PP × 100).
PWV was measured using a tonometer to capture the carotid waveform, while a femoral cuff was
placed high on the left thigh in order to capture the femoral waveform. The PWV was then calculated
by dividing the distance between the carotid and femoral measurement sites by the transit time.
This method is considered the gold standard technique for assessing central arterial stiffness.
2.4. Sample Size Calculation
Power calculations showed that a sample size of 40 was adequate to provide sufficient statistical
power to detect a statistically significant between-group difference of 5% and a standard deviation (SD)
of 11 in HDL-C efflux levels (i.e., the primary outcome of the OLIVAUS study), with 80% power and 5%
level of significance [30]. The total sample size was set at 50 study participants, in order to also account
for an attrition rate of 20%. Although, the selected sample was adequate for the examination of HDL-C
efflux, this might not be the case for the secondary outcomes of the OLIVAUS study, including BP and
measures of arterial stiffness.
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2.5. Statistical Analysis
All statistical analyses were conducted using the SPSS statistical software for Windows (IBM,
version 24.0; IBM, Armonk, NY, USA). For all continuous variables, the Kolmogorov–Smirnov test was
performed to examine the normality of their distribution. A general linear model, i.e., repeated-measures
ANOVA (analysis of variance), was used to examine the between-group differences (treatment effect,
i.e., extra virgin high vs. low polyphenol OO) of mean values at each time point of measurement,
the within-group changes (time effect) from baseline to follow up in each intervention arm, and the
differences in the changes from baseline to follow up between the two intervention arms (treatment ×
time interaction effect). Both per protocol (PP) and intention-to-treat (ITT) analyses were performed.
The PP analyses were conducted in study participants who had full data from baseline to follow
up in the first or the second intervention period. For the ITT analyses, multiple imputations were
conducted in order to compensate for all missing values. Five imputed models derived from this
process. Considering that the PP and the ITT analyses provided similar results (i.e., mean values, mean
changes and statistical significance), the results coming from the latter are presented in this article.
In all statistical analyses, adjustments were made for gender and age. Data are presented either as the
mean ± SD, as estimated marginal means and standard errors (SE) or as the mean change and 95%
confidence interval of change (CI) for continuous variables and as frequency (n) and percentage (%) for
categorical ones. All reported p values are two tailed, and the level of statistical significance is set at
p < 0.05.
3. Results
Fifty volunteers (n = 33 females, and n = 17 males), from 105 interested individuals who
agreed to be screened, were eligible and enrolled in the study from July 2018 through to October
2019. Seven participants discontinued the intervention, due to inability to comply (n = 4) and for
personal reasons, (n = 3) and therefore 43 participants completed the study. Figure 1 provides the
study participant flow diagram. Minor adverse events were recorded after the consumption of both
intervention OOs, with nausea and heart burn being the most common symptoms. The proportion of
participants that experienced symptoms of nausea (24%) and heart burn (6%) was comparable between
the HPOO and LPOO group.
3.1. Baseline Characteristics of Study Participants
Table 1 presents the descriptive characteristics of study participant socio-demographics,
anthropometrics and hemodynamic indices in the total sample (n = 50) and by gender. Study
participants had a mean age of 38.5 ± 13.9 years (the age range was between 20 and 70 years) and
their mean years of education was 17.3 ± 3.5. In addition, the majority of study participants were
females (66%), had a tertiary education (86%) and were born in Australia (70%). No significant gender
differences were observed in any of these socio-demographic characteristics. The mean BMI and
WC was 24.7 ± 3.5 kg/m2 and 86.9 ± 11.2 cm, respectively, with no significant differences between
genders. In addition, 44% of study participants were overweight and 4% were obese. Based on their
WC measurements, 16% had a high cardiometabolic risk and 24% had very high risk. Although there
were no significant differences between genders observed in BMI and WC, compared to females, male
study participants were taller (179.3 ± 6.8 cm vs. 163.6 ± 5.8 cm, p < 0.001) and had a higher body
weight (79.6 ± 9.6 kg vs. 66.1 ± 11.9 kg, p < 0.001). At baseline, the mean peripheral SBP and DBP for
the cohort was 120.0 ± 13.4 and 69.9 ± 8.4 mmHg, respectively, while 18% of study participants were
categorised as having elevated BP, 20% had Stage 1 Hypertension and 8% had Stage 2 Hypertension.
Mean central SBP and DBP was 106.8 ± 13.3 and 70.6 ± 8.7 mmHg, respectively, mean heart rate was
61.5 ± 10.2 bpm and PWV was 9.5 ± 1.4 m/s. There were no significant differences between genders in
any of these hemodynamic indices.
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Socio-Demographics Mean (SD) Mean (SD) Mean (SD)
Age (years) 38.5 (13.9) 33.4 (11.6) 41.2 (14.4) 0.058
Education (years) 17.3 (3.5) 17.4 (3.7) 17.2 (3.5) 0.895
Highest Level of Education n (%) n (%) n (%) 0.241
Secondary School 2 (4.0) 0 (0.0) 2 (6.1)
Tertiary 43 (86.0) 17 (100.0) 26 (78.8)
Trade 2 (4.0) 0 (0.0) 2 (6.1)
Other 3 (6.0) 0 (0.0) 3 (9.1)
Country of Birth 0.798
Australia, NZ, Pacific Islanders 35 (70.0) 11 (64.7) 24 (72.7)
Europe 5 (10.0) 2 (11.8) 3 (9.1)
South America 4 (8.0) 1 (5.9) 3 (9.1)
Middle East and Asia 6 (12.0) 3 (17.6) 3 (9.1)
Anthropometrics Mean (SD) Mean (SD) Mean (SD)
Height (cm) 168.9 (9.6) 179.3 (6.8) 163.6 (5.8) <0.001
Weight (Kg) 70.7 (12.8) 79.6 (9.6) 66.1 (11.9) <0.001
BMI (kg/m2) 24.7 (3.5) 24.7 (2.4) 24.6 (3.9) 0.915
Waist Circumference (cm) 86.9 (11.2) 88.9 (8.7) 85.9 (12.3) 0.364
Weight Status Categories † n (%) n (%) n (%)
Underweight 1 (2.0) 1 (3.0) 0 (0) 0.649
Normal Weight 25 (50.0) 16 (48.5) 9 (52.9)
Overweight 22 (44.0) 14 (42.4) 8 (47.1)
Obese 2 (4.0) 2 (6.1) 0 (0)
Waist Circumference Categories ‡
Normal 25 (50.0) 13 (39.4) 12 (70.6) 0.105
High Risk 8 (16.0) 6 (18.2) 2 (11.8)
Very High Risk 17 (34.0) 14 (42.4) 3 (17.6)
Hemodynamic Indices
Peripheral Blood Pressure Mean (SD) Mean (SD) Mean (SD)
Peripheral SBP (mmHg) 120.0 (13.4) 121.7 (9.1) 119.1 (15.2) 0.454
Peripheral DBP (mmHg) 69.9 (8.4) 69.7 (8.9) 70.0 (8.3) 0.904
Peripheral Blood Pressure Categories § n (%) n (%) n (%)
Normal Blood Pressure 27 (54.0) 20 (60.6) 7 (41.2) 0.399
Elevated Blood Pressure 9 (18.0) 4 (12.1) 5 (29.4)
Hypertension Stage 1 10 (20.0) 6 (18.2) 4 (23.5)
Hypertension Stage 2 4 (8.0) 3 (9.1) 1 (5.9)
Central Blood Pressure Mean (SD) Mean (SD) Mean (SD)
Central Aortic SBP (mmHg) 106.8 (13.3) 106.9 (8.5) 106.8 (15.3) 0.971
Central Aortic DBP (mmHg) 70.6 (8.7) 70.3 (9.1) 70.8 (9.7) 0.843
Pulse Pressure (mmHg) 36.0 (8.9) 36.2 (7.9) 35.9 (9.5) 0.930
Heart Rate (bpm) 61.5 (10.2) 58.1 (8.9) 63.2 (10.4) 0.092
Systemic Arterial Stiffness
Augmented Pressure (mmHg) 6.8 (6.8) 4.8 (4.2) 7.8 (7.6) 0.077
Augmented Index (%) 16.6 (14.9) 12.2 (9.4) 18.9 (16.8) 0.077
Pulse Wave Velocity (m/s) 9.5 (1.4) 9.5 (1.3) 9.5 (1.5) 0.933
* p-values were derived from the Student’s t-test for continuous variables and from the chi-square test for categorical
variables. Results in bold indicate p < 0.05, and are therefore statistically significant. BMI, body mass index; BP, blood
pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; †: Weight status categories: Underweight, BMI
< 18.5 kg/m2; Normal weight, 18.5 ≤ BMI < 25 kg/m2; Overweight, 25 ≤ BMI < 30 kg/m2; Obese, BMI ≥ 30 kg/m2.
‡: Waist circumference categories: Normal, WC < 80 cm in women and <94 cm in men; High risk, 80–88 cm in
women and 94–102 cm in men; Very high risk: WC > 88 cm in women and >102 cm in men. §: Peripheral BP
categories: Normal BP, SBP < 120 and DBP < 80 mmHg; Elevated BP, SBP > 120–129.9 and DBP < 80 mmHg;
Hypertension Stage 1, SBP 130–139.9 or DBP 80–89.9 mmHg; Hypertension Stage 2, SBP > = 140 or DBP > = 90.
3.2. Effect of LPOO and HPOO on Dietary Intake and Physical Activity
The changes observed in dietary energy, macro- and micronutrient intake from baseline to follow
up, as well as the differences between treatment arms are summarized in Table 2. The changes from
baseline to follow up were not significantly different between the two treatment arms. However, dietary
energy intake increased significantly in participants following LPOO (by 1806.1 kJ/day, 95% CI: 1075.4
to 2536.8) and HPOO (by 1766.6 kJ/day, 95% CI: 1035.9 to 2497.3). Consumption of LPOO and HPOO
also significantly increased intake of total fat (by 49.3 g/day, 95% CI: 41.1 to 57.4 and 46.0 g/day, 95% CI:
37.8 to 54.1, respectively), SFA (by 7.4 g/day, 95% CI: 4.0 to 10.8 and 6.5 g/day, 95% CI: 3.1 to 9.9,
respectively), MUFA (by 36.8 g/day, 95% CI: 33.2 to 40.3 and by 35.1 g/day, 95% CI: 31.6 to 38.6,
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respectively) and PUFA (by 3.1 g/day, 95% CI: 1.0 to 5.1 and by 3.0 g/day, 95% CI: 1.0 to 5.1, respectively).
In addition, no significant within-group changes or between-group differences were observed in
the other examined macronutrients (protein, carbohydrates and dietary fibre), nor in micronutrients
such as sodium, potassium, magnesium and calcium, including caffeine. Regarding physical activity,
no within-group changes or between-group differences were observed in the time study participants
were engaged in physical activities of moderate–vigorous intensity over the intervention period (data
not shown).
Table 2. Effect of low polyphenol OO vs. high polyphenol OO on mean changes in dietary energy,





Mean Change (95% CI)
(Time Effect)
p-Value
(Treatment * Time Effect)
Energy intake (KJ/day)
Low Polyphenol OO (n = 50) 8712.8 (328.3) 10518.9 (344.4) 1806.1 (1075.4 to 2536.8)
0.940High Polyphenol OO (n = 50) 8892.6 (328.3) 10659.2 (344.4) 1766.6 (1035.9 to 2497.3)
p-value (Treatment effect) 0.700 0.774
Protein intake (g/day)
Low Polyphenol OO (n = 50) 102.0 (5.5) 100.7 (5.2) −1.3 (−14.3 to 11.8)
0.924High Polyphenol OO (n = 50) 97.4 (5.5) 97.0 (5.3) −0.4 (−13.4 to 12.7)
p-value (Treatment effect) 0.558 0.619
Carbohydrates (g/day)
Low Polyphenol OO (n = 50) 214.8 (10.1) 213.4 (11.1) −1.5 (−23.5 to 20.6)
0.972High Polyphenol OO (n = 50) 219.9 (10.1) 217.8 (11.1) −2.0 (−24.0 to 20.0)
p-value (Treatment effect) 0.726 0.776
Total fat intake (g/day)
Low Polyphenol OO (n = 50) 79.9 (4.0) 129.2 (4.5) 49.3 (41.1 to 57.4)
0.571High Polyphenol OO (n = 50) 84.3 (4.0) 130.3 (4.5) 46.0 (37.8 to 54.1)
p-value (Treatment effect) 0.441 0.870
SFA intake (g/day)
Low Polyphenol OO (n = 50) 27.7 (1.5) 35.1 (1.9) 7.4 (4.0 to 10.8)
0.707High Polyphenol OO (n = 50) 28.8 (1.5) 35.3 (1.9) 6.5 (3.1 to 9.9)
p-value (Treatment effect) 0.620 0.953
MUFA intake (g/day)
Low Polyphenol OO (n = 50) 30.6 (1.7) 67.3 (1.9) 36.8 (33.2 to 40.3)
0.514High Polyphenol OO (n = 50) 31.8 (1.7) 67.0 (1.9) 35.1 (31.6 to 38.6)
p-value (Treatment effect) 0.605 0.877
PUFA intake (g/day)
Low Polyphenol OO (n = 50) 14.6 (1.0) 17.7 (1.0) 3.1 (1.0 to 5.1)
0.971High Polyphenol OO (n = 50) 15.7 (1.0) 18.7 (1.0) 3.0 (1.0 to 5.1)
p-value (Treatment effect) 0.483 0.469
Fibre intake (g/day)
Low Polyphenol OO (n = 50) 29.7 (1.7) 30.7 (1.8) 0.9 (−3.1 to 4.9) 0.314
High Polyphenol OO (n = 50) 29.6 (1.7) 33.5 (1.8) 3.8 (−0.2 to 7.8)
p-value (Treatment effect) 0.963 0.268
Sodium intake (mg/day)
Low Polyphenol OO (n = 50) 2611.1 (269.5) 2287.1 (168.9) −324.0 (−878.2 to 230.3) 0.994
High Polyphenol OO (n = 50) 3096.7 (269.5) 2775.5 (168.9) −321.2 (−875.5 to 233.1)
p-value (Treatment effect) 0.206 0.044
Potassium intake (mg/day)
Low Polyphenol OO (n = 50) 3486,7 (227.0) 3389.3 (170.5) −97.3 (−631.1 to 436.4) 0.488
High Polyphenol OO (n = 50) 3334.4 (227.0) 3501.9 (170.5) 167.5 (−366.2 to 701.3)
p-value (Treatment effect) 0.636 0.642
Magnesium intake (mg/day)
Low Polyphenol OO (n = 50) 574.2 (92.9) 446.0 (18.9) −128.2 (−308.4 to 52.0) 0.271
High Polyphenol OO (n = 50) 433.6 (92.9) 447.6 (18.9) 14.0 (−166.2 to 194.2)
p-value (Treatment effect) 0.287 0.953
Calcium intake (mg/day)
Low Polyphenol OO (n = 50) 1005.0 (92.3) 1056.2 (95.6) 51.1 (−205.1 to 307.3) 0.916
High Polyphenol OO (n = 50) 977.3 (92.3) 1009.2 (95.6) 31.9 (−224.3 to 288.1)
p-value (Treatment effect) 0.832 0.729
Caffeine intake (mg/day)
Low Polyphenol OO (n = 46) 199.4 (54.1) 182.0 (35.6) −17.4 (−122.3 to 87.6) 0.612
High Polyphenol OO (n = 43) 242.8 (56.0) 186.7 (36.8) −56.1 (−164.6 to 52.5)
p-value (Treatment effect) 0.578 0.926
All statistical analyses were adjusted for gender and age. Results in bold indicate statistical significance (p < 0.05).
OO, olive oil; SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids;
SEM, standard error of the mean; CI, confidence interval.
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3.3. Effect of LPOO and HPOO on Anthropometrics
Table 3 summarizes the changes observed in anthropometric indices from baseline to follow up
and the relevant differences between the two intervention arms. There was a small but significant
increase in body weight by 0.4 kg (95% CI: 0.2 to 0.7) following the LPOO intervention, but this
change was not found to differ compared to the non-significant change observed in HPOO group.
No within-group changes or between-group differences were observed in BMI and WC after the daily
consumption of the two intervention oils.











Low Polyphenol OO (n = 50) 70.8 (1.5) 71.2 (1.5) 0.4 (0.2 to 0.7)
0.163High Polyphenol OO (n = 50) 70.7 (1.5) 70.9 (1.5) 0.2 (−0.1 to 0.4)
p-value (Treatment * effect) 0.993 0.902
Height (cm)
Low Polyphenol OO (n = 50) 168.9 (0.9) 169.0 (0.9) 0.1 (−0.2 to 0.4)
0.890High Polyphenol OO (n = 50) 168.9 (0.9) 169.0 (0.9) 0.1 (−0.1 to 0.4)
p-value (Treatment effect) 0.974 0.992
BMI (kg/m2)
Low Polyphenol OO (n = 50) 24.7 (0.4) 24.8 (0.4) 0.1 (−0.01 to 0.2)
0.305High Polyphenol OO (n = 50) 24.7 (0.4) 24.7 (0.4) 0.02 (−0.1 to 0.1)
p-value (Treatment effect) 0.993 0.897
Waist circumference (cm)
Low Polyphenol OO (n = 50) 87.1 (1.3) 87.4 (1.2) 0.3 (−0.1 to 0.7)
0.501High Polyphenol OO (n = 50) 87.1 (1.3) 87.3 (1.2) 0.1 (−0.2 to 0.5)
p-value (Treatment effect) 1.000 0.919
All statistical analyses were adjusted for gender and age. Results in bold indicate statistical significance (p < 0.05).
OO, olive oil; SEM, standard error of the mean; CI, confidence interval.
3.4. Effect of LPOO and HPOO on Peripheral BP, Central BP and Arterial Stiffness
The effect of the two intervention OOs on peripheral and central BP are illustrated in Figure 2.
The changes from baseline to follow up were not significantly different between the two treatment
arms. However, compared to baseline, peripheral (brachial) and central (aortic) SBP was significantly
reduced after HPOO by 2.5 mmHg (95% CI: −4.7 to −0.3) and by 2.7 mmHg (95% CI: −4.7 to −0.6),
respectively. No other significant within-group changes or between-group differences were observed
in peripheral and central DBP, as well as in the rest of the examined hemodynamic (i.e., PP and HR)
and arterial stiffness indices (i.e., AP, AIx and PWV) (Table 4).
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Mean Change (95% CI)
(Time Effect)
p-Value
(Treatment * Time Effect)
Pulse pressure (mmHg)
Low Polyphenol OO (n = 50) 35.7 (1.0) 36.4 (1.0) 0.7 (−0.8 to 2.1)
0.296High Polyphenol OO (n = 50) 36.3 (1.0) 35.9 (1.0) −0.4 (−1.9 to 1.1)
p-value (Treatment effect) 0.653 0.723
Pulse rate (bpm)
Low Polyphenol OO (n = 50) 61.1 (1.3) 59.4 (1.4) −1.7 (−3.9 to 0.4)
0.403High Polyphenol OO (n = 50) 61.0 (1.3) 60.6 (1.4) −0.4 (−2.6 to 1.7)
p-value (Treatment effect) 0.954 0.553
Augmented pressure (mmHg)
Low Polyphenol OO (n = 50) 6.5 (0.7) 6.0 (0.7) −0.5 (−1.6 to 0.6)
0.987High Polyphenol OO (n = 50) 6.9 (0.7) 6.3 (0.7) −0.5 (−1.6 to 0.5)
p-value (Treatment effect) 0.692 0.714
Augmented index (%)
Low Polyphenol OO (n = 50) 16.2 (1.7) 14.6 (1.8) −1.7 (−4.2 to 0.8)
0.807High Polyphenol OO (n = 50) 16.6 (1.7) 15.4 (1.8) −1.2 (−3.7 to 1.3)
p-value (Treatment effect)
Pulse wave velocity (m/s)
Low Polyphenol OO (n = 50) 9.6 (0.1) 9.5 (0.1) −0.03 (−0.3 to 0.2)
0.926High Polyphenol OO (n = 50) 9.5 (0.1) 9.4 (0.1) −0.05 (−0.3 to 0.2)
p-value (Treatment effect) 0.679 0.608
All statistical analyses were adjusted for gender and age. OO, olive oil; SEM, standard error of the mean;
CI, confidence interval.
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Figure 2. Effect of 3-weeks daily consumption of extra virgin high polyphenol olive oil (HPOO;
360 mg/kg polyphenols) and low polyphenol OO (LPOO; 86 mg/kg polyphenols) on mean peripheral
(A) and central (B) blood pressure. N = 50 part cipants. SBP, systolic blood pressure; DBP, diastolic blood
pressure. Data are mean±standard deviation. The P values in the Figure indicate the between-group
differences in the changes from baseline to follow-up (treatment*time effect) for each blood pressure
measure. The asterisk (*) indicates significance (p < 0.05) of within-group changes from baseline
to follow-up.
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3.5. Compliance to Treatment
Compliance to treatment was high, as reflected in the OO volume returned by participants after
each intervention period. Based on the measured actual remaining OO, compliance was found to be
92% for both the LPOO and HPOO group after the first intervention period, while 92% for the LPOO
group and 90% for the HPOO group after the second intervention period. Nevertheless, compliance
was not found to differ significantly between the two groups (Supplementary Table S1).
4. Discussion
The present double-blind, cross-over, randomized controlled trial investigated the effect of daily
consumption of 60 mL raw extra virgin HPOO in comparison with LPOO, each for 3 weeks, on BP and
arterial stiffness in Australian adults. The key finding was that peripheral and central SBP decreased
significantly by 2.5 and 2.7 mmHg, respectively, after extra virgin HPOO (phenolic content 360 mg/kg)
consumption. However, no significant differences were observed between the two interventions
with regards to the changes in peripheral and central SBP. No significant within-group changes or
between-group differences were either observed on diastolic BP, and measures of arterial stiffness.
The significant decrease reported from our study in peripheral SBP is consistent with the limited
number of RCTs that have examined the effect of HPOO consumption on peripheral BP, but after
providing different doses of OO, different phenolic content of the administered oil, and varying
intervention duration. In this regard, Moreno-Luna et al. [24] described that daily consumption of
60 mL HPOO with the highest phenolic content reported in the published literature (i.e., 564 mg/kg) for
8 weeks, significantly reduced peripheral SBP and DBP (by 7.9 and 6.6 mmHg, respectively) compared
to ROO with no polyphenols, in young women with mild hypertension. Using an OO with high
polyphenol concentration comparable to our study, Bondia-Pons et al. [31] reported that 9 weeks
daily consumption of 25 mL of OO (366 mg/kg of polyphenols) significantly decreased peripheral
SBP (~2.4 to 4.4 mmHg) in healthy non-Mediterranean men living in Europe. Other authors have
described that 3 weeks daily consumption of 25 mL of HPOO (366 mg/kg of polyphenols) induced a
significant reduction in peripheral SBP by 4.2 mmHg, through modulating the expression of genes
that are related to the renin–angiotensin–aldosterone system (RAAS) [32]. In agreement with our
results, the two aforementioned studies did not show any significant changes in peripheral DBP.
These findings are supported by a recent meta-analysis, reporting that consumption of OOs with
at least 150 mg/kg polyphenols significantly reduces peripheral SBP but not peripheral DBP [26],
although there is evidence coming from one clinical trial indicating that OO with less phenolic content
might also exert SBP-lowering effects. In this context, the NUTRAOLEUM study showed that daily
consumption of 30 mL of virgin OO (phenolic content, 124 mg/kg) for 3 weeks significantly reduced
peripheral SBP by 2.0 mmHg but not peripheral DBP, in healthy adults [33].
It is noteworthy, that other clinical trials also examining the effect of HPOO on peripheral SBP
and DBP reported either significant results only for peripheral DBP or no significant findings on BP.
In this regard, the EUROLIVE study demonstrated that 3 weeks of daily consumption of 25 mL EVOO,
containing 366 mg/kg of polyphenols, significantly reduced peripheral DBP, but had no effect on SBP
in healthy men [34], while another recent meta-analysis showed no significant pooled effect of the
consumption of HPOO (150 to 800 mg/kg phenolic content) on peripheral SBP and DBP [19].
To the best of our knowledge, this is the first study reporting a significant reduction in central SBP
after consumption of HPOO. This is of importance, considering that raised central BP has been positively
associated with cardiovascular risk and mortality [16,35]. The effect of different bioactive nutrients
(e.g., omega 3 fish oils, Vitamin C, and Vitamin E) on central hemodynamic markers (i.e., central
SBP and DBP), either in the acute postprandial state or after long-term use, has been previously
reported [36]. However, there is currently no evidence stemming from long-term RCTs regarding the
effects of OO polyphenols alone, on these markers. Considering the scarcity of evidence and although
not directly comparable with our study, Papamichael et al. [16] reported significant postprandial
reductions in both central SBP and DBP, ranging from 3 to 5 mmHg, after the consumption of meals
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combining OO and red wine by healthy study participants. However, the combined meal design
makes it difficult to give attribution to the OO and/or wine for the favourable effects observed on
central BP. The study’s authors proposed that certain nutrients may exert a decrease in peripheral
resistance, and consequently wave reflections and left ventricular afterload, thus resulting in a decrease
in central SBP [16]. However, the mechanisms by which virgin OO minor compounds might exert
their beneficial effects on central hemodynamic markers remain unclear. Therefore, further studies are
warranted to reach final conclusions about the effect of OO polyphenols on central SBP and/or DBP.
Dietary intake and body weight changes observed in our study deserve comment in the context
of the favourable effect of HPOO on peripheral and central SBP. In this regard, the addition of 60 mL of
OO in participants’ habitual diet resulted in significant increases in caloric intake leading to weight gain
in both intervention groups. Previous cross-sectional and prospective studies have reported that body
weight gain is directly associated with increases in arterial BP in normotensive subjects [37], with a 1
kg increase in body weight predicting a 0.63 and 0.42 mmHg increase in SBP and DBP, respectively [38].
Based on the above, the increases in body weight of 0.2 and 0.4 kg observed in the HPOO and LPOO
group, respectively, would be expected to lead to corresponding increases in BP. However, that was
not the case in our study, indicating a potential counterbalancing effect of OO polyphenols on weight
gain. In this regard, the phenolic content of 360 mg/Kg in HPOO, which was much higher compared
with the effective threshold of 150 mg/kg reported by a recent meta-analysis [26], could provide a basis
for interpreting the significant reduction in peripheral and central SBP observed in this group, despite
the non-significant weight gain of 0.2 kg.
Further to dietary energy intake, our study also recorded the intake of macro- (i.e., protein
and dietary fibre) and micronutrients (i.e., sodium, potassium, magnesium and calcium) that have
established effects on BP levels [39–42]. In this regard, there were no differences between the two
intervention arms, indicating that the only dietary factor which could account for the observed
favourable effect to reduce SBP, was the higher phenolic content in HPOO compared to LPOO.
However, it is not clear why the higher phenolic content in HPOO has a significant lowering effect only
on SBP but not on DBP. It could be speculated that both quantity (i.e., dose) and quality (i.e., chemical
structure) of polyphenols in EVOO may exert differential effects on the vascular system [43,44].
Nevertheless, further clinical trials are required to examine the effect of OOs with different phenolic
profile on BP, arterial stiffness and other cardiometabolic risk markers.
To the best of our knowledge, the OLIVAUS study is the first human clinical trial to investigate the
effect of OO polyphenols on measures of arterial stiffness through applanation tonometry. Stiffening
of the arterial wall in the larger central arterial system represents an important CVD risk marker [6]
and the early detection of such abnormalities can inform relevant preventive or treatment initiatives.
However, the present study did not detect within-group changes or between-group differences in
any measures of arterial stiffness after either OO intervention. The absence of significant findings
may be partly attributed to our study being adequately powered for its primary outcome, while this
might not be the case for the secondary outcomes, including measures of arterial stiffness. Despite
the scarcity of evidence in this field, there is a large body of published literature documenting the
effect of polyphenols on biochemical markers of endothelial function, which also represent other
surrogate measures of arterial stiffness. In this context, Sanchez-Rodriquez et al. [33] investigated
the effect of three virgin OOs enriched with polyphenols (124, 490 and 487 mg/kg) and triterpenes
(86 ppm, 86 ppm and 389 ppm, respectively) on endothelial function biomarkers in healthy adults.
These investigators reported significant reductions in plasma levels of the vasoconstrictor hormone
endothelin-1 at the end of the three interventions and regardless of triterpene content. In another
clinical trial in women with mild hypertension, daily consumption of extra virgin HPOO (564 mg/kg
polyphenols) for 8 weeks significantly decreased plasma levels of asymmetrical dimethylarginine
(ADMA), which is a surrogate marker of poor endothelial function [45]. The participants also had
significantly increased concentrations of vasodilating nitric oxide (NO) molecule after the intervention,
supporting a beneficial effect of high polyphenol OO on endothelial function [24,45].
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The findings reported in our study should be interpreted in light of its strengths and limitations.
The main strength of the present study is its randomized, double-blind, cross-over design that reduces
interindividual variability and increases the external validity of the study findings. The use of
applanation tonometry represents another strength, since it is a state-of-the-art, non-invasive method
to measure BP and arterial stiffness. In addition, in a multiethnic population that is not accustomed to a
high consumption of OO, our participants’ compliance was overall high throughout both intervention
periods. On the other hand, one of the limitations of the present study is that the sample size was
calculated on the basis of the expected differences only in its primary outcome (i.e., HDL-efflux).
Another limitation could be the potential effect of seasonality on the examined outcomes, due to the
fact that the participants were enrolled in the study gradually (i.e., from July 2018 through to October
2019). Lastly, despite the inclusion of a washout period before the initiation of the intervention and
between the intervention periods, there is no guarantee that any potential carry-over effect on the
examined hemodynamic markers was completely avoided. However, pairwise comparisons that
examined potential carry-over effects were insignificant for all hemodynamic markers.
5. Conclusions
To our knowledge, the OLIVAUS study is the first to examine the effect of OO polyphenols on
peripheral and central SBP and DBP as well as on measures of arterial stiffness in Australian adults.
Although there were no significant differences between OO treatments in any of the examined outcomes,
there was a significant reduction in peripheral and central SBP after daily consumption of extra virgin
HPOO for 3 weeks. This provides evidence for a potentially widely accessible dietary intervention that
can reduce CVD risk in a multicultural context, such as in Australia. However, additional clinical trials
of longer duration and use of EVOO with different phenolic content and profile are required to shed
more light on the potential effect of OO polyphenols on other CVD risk markers, including DBP and
arterial stiffness.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/12/8/2272/s1,
Table S1: Summary of olive oil volume returned by participants following the two diet interventions.
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